• Efficient Synthesis of Deuterium-Labeled Degarelix Acetate

  2026-06-04

  This study introduces a robust, multi-step protocol for synthesizing deuterium-labeled degarelix acetate—a pivotal internal standard for clinical pharmacokinetics and androgen-related disease research. The methodology streamlines isotope incorporation and peptide assembly, enhancing the reproducibility and scalability of tracer studies in advanced metabolic and drug development workflows.

• Annular Sector Microneedle Enables Targeted Gene Delivery fo

  2026-06-03

  This study presents an engineered annular sector-shaped microneedle patch for localized co-delivery of nicotinamide and Nmnat1 gene-loaded lipid nanoparticles to the trabecular meshwork, reversing mitochondrial dysfunction in glaucoma. The approach demonstrates improved bioavailability, intraocular pressure control, and restoration of tissue function, highlighting a novel combinatorial platform for targeted ocular gene therapy.

• TG003: Potent Cdc2-like Kinase Inhibitor for Splicing Resear

  2026-06-03

  TG003 is a nanomolar-potency Cdc2-like kinase inhibitor used to dissect alternative splicing mechanisms and model platinum resistance in cancer. It acts selectively on Clk1 and Clk4, modulating splice site selection by inhibiting SR protein phosphorylation. TG003 supports translational workflows from mechanistic cancer studies to exon-skipping therapy development.

• A1 vs. AMD3100: Advancing CXCR4 Inhibition in Colorectal Can

  2026-06-02

  The reference study introduces A1, a novel fluorinated CXCR4 inhibitor, and demonstrates its superior anti-tumor efficacy over AMD3100 in colorectal cancer models. These findings highlight the evolving landscape of CXCR4-targeted therapies and suggest new avenues for cancer metastasis inhibition research.

• Verbascoside: Advanced PKC/NF-κB Inhibition in Neuroinflamma

  2026-06-02

  Explore how Verbascoside serves as a precise PKC/NF-κB inhibitor, uniquely bridging bone metabolism and neuroinflammation studies. Discover mechanistic insights, protocol guidance, and scientific context grounded in the latest research.

• Gastrin I (human): Reliable Solutions for GI Assay Challenge

  2026-06-01

  This article examines common experimental challenges in gastric acid secretion pathway research and demonstrates how 'Gastrin I (human)' (SKU B5358) from APExBIO addresses reproducibility, compatibility, and interpretability in advanced in vitro assays. Scenario-driven Q&A blocks guide biomedical researchers in leveraging this high-purity peptide for robust gastrointestinal physiology studies.

• BIBR 1532: Telomerase Inhibitor Workflows for Cancer Researc

  2026-06-01

  BIBR 1532 stands out as a selective telomerase inhibitor, enabling precise suppression of telomerase activity and apoptosis induction in cancer models. This article provides actionable workflows, troubleshooting tips, and cross-links to emerging telomere-targeting strategies, empowering researchers to optimize telomerase assays and interrogate cancer cell proliferation pathways.

• TG003 Cdc2-like Kinase Inhibitor: Workflows for Splicing Res

  2026-05-31

  TG003 empowers researchers to dissect and modulate alternative splicing with unmatched selectivity in both cancer and neuromuscular disease models. This guide translates the latest mechanistic findings into actionable protocols, troubleshooting strategies, and advanced applications, making TG003 from APExBIO a reference tool for translational scientists.

• Nebivolol Hydrochloride: Benchmarking β1-Selectivity in Tran

  2026-05-30

  This article explores the mechanistic and strategic dimensions of Nebivolol hydrochloride as a selective β1-adrenoceptor antagonist. Bridging recent advances in drug discovery with translational cardiovascular research needs, we dissect the unique position of Nebivolol hydrochloride in enabling rigorous, pathway-specific studies free from mTOR interference. Integrating new evidence from yeast-based screening platforms and a critical review of the competitive landscape, we provide actionable guidance for researchers focused on cardiovascular pharmacology, hypertension, and heart failure.

• Prevotella copri Depletes IPyA to Promote Breast Cancer Prog

  2026-05-29

  This study identifies Prevotella copri as an oncogenic gut microbe in breast cancer, revealing that its enrichment exhausts host indole-3-pyruvic acid (IPyA) and disrupts anti-cancer signaling via UHRF1 and AMPK pathways. The mechanistic insights clarify a direct microbiome–host metabolite axis influencing tumor growth, with implications for targeted intervention and protein detection workflows.

• Nonivamide (Capsaicin Analog): New Frontiers in TRPV1-Mediat

  2026-05-29

  Explore how Nonivamide, a selective capsaicin analog, is unlocking advanced research in TRPV1-driven cancer cell growth inhibition and inflammation modulation. This article delivers unique experimental strategies and translational insight distinct from existing resources.

• Cathepsin B inhibitor CA-074: Protocols, QC, and Limitations

  2026-05-28

  Cathepsin B inhibitor CA-074 (SKU A1926) enables targeted inhibition of cathepsin B in research applications, supporting studies in cancer metastasis, neurotoxicity, and immune modulation where high selectivity and stability are required. It should not be used when broad-spectrum cysteine protease inhibition or long-term solution stability at room temperature is needed. Researchers benefit from product-specific guidance to maximize selectivity and reproducibility.

• Risedronate Sodium: Innovations in Delivery and Mechanistic

  2026-05-28

  Explore how Risedronate Sodium, a potent FPP synthase inhibitor, is revolutionizing osteoporosis and emphysema research through advanced delivery systems and mechanistic insights. This article uniquely details bioavailability breakthroughs and cross-disciplinary protocols for bone and respiratory studies.

• TG003 Cdc2-like Kinase Inhibitor: Workflows for Splicing Mod

  2026-05-27

  TG003 delivers precise, ATP-competitive inhibition of Clk kinases, enabling unparalleled control of alternative splicing in disease models. Its nanomolar potency and selectivity make it the gold-standard for dissecting platinum resistance and advancing exon-skipping therapy.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-05-27

  This article reviews recent advances in the discovery of allosteric PDK4 inhibitors as reported by Lee et al., highlighting the development of compound 8c with potent metabolic, anti-allergic, and anticancer effects. Implications for metabolic disease treatment and cross-talk with dopaminergic signaling research are discussed.

7858 records 13/524 page Previous Next First page 上5页 1112131415 下5页 Last page